Your browser doesn't support javascript.
loading
WNT/ß-Catenin Pathway and Epigenetic Mechanisms Regulate the Pitt-Hopkins Syndrome and Schizophrenia Risk Gene TCF4.
Hennig, Krista M; Fass, Daniel M; Zhao, Wen-Ning; Sheridan, Steven D; Fu, Ting; Erdin, Serkan; Stortchevoi, Alexei; Lucente, Diane; Cody, Jannine D; Sweetser, David; Gusella, James F; Talkowski, Michael E; Haggarty, Stephen J.
Affiliation
  • Hennig KM; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Fass DM; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Zhao WN; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Sheridan SD; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Fu T; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Erdin S; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Stortchevoi A; Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts, USA.
  • Lucente D; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Cody JD; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Sweetser D; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
  • Gusella JF; Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Massachusetts, USA.
  • Talkowski ME; Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
  • Haggarty SJ; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Mol Neuropsychiatry ; 3(1): 53-71, 2017 Jul.
Article in En | MEDLINE | ID: mdl-28879201
Genetic variation within the transcription factor TCF4 locus can cause the intellectual disability and developmental disorder Pitt-Hopkins syndrome (PTHS), whereas single-nucleotide polymorphisms within noncoding regions are associated with schizophrenia. These genetic findings position TCF4 as a link between transcription and cognition; however, the neurobiology of TCF4 remains poorly understood. Here, we quantitated multiple distinct TCF4 transcript levels in human induced pluripotent stem cell-derived neural progenitors and differentiated neurons, and PTHS patient fibroblasts. We identify two classes of pharmacological treatments that regulate TCF4 expression: WNT pathway activation and inhibition of class I histone deacetylases. In PTHS fibroblasts, both of these perturbations upregulate a subset of TCF4 transcripts. Finally, using chromatin immunoprecipitation sequencing in conjunction with genome-wide transcriptome analysis, we identified TCF4 target genes that may mediate the effect of TCF4 loss on neuroplasticity. Our studies identify new pharmacological assays, tools, and targets for the development of therapeutics for cognitive disorders.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Mol Neuropsychiatry Year: 2017 Document type: Article Affiliation country: United States Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Mol Neuropsychiatry Year: 2017 Document type: Article Affiliation country: United States Country of publication: Switzerland